FDA’s New Software Validation Requirements Explained

Illustration of three professionals reviewing tablets and documents beneath an FDA inspection sign

FDA software validation requirements depend on the software’s intended use and the regulatory framework that applies. FDA’s February 2026 guidance on Computer Software Assurance for Production and Quality Management System Software addresses software used in medical-device production or the quality management system. It should not be read as a universal replacement for pharmaceutical or clinical-system validation obligations.

Start with scope: distinguish medical-device production and QMS software, drug-manufacturing systems, clinical-investigation systems, and software that is itself a medical device. They raise different regulatory questions.

What changed in FDA’s software assurance guidance?

The February 2026 final guidance supersedes the September 2025 version. It describes risk-based assurance and testing approaches for medical-device production and QMS automation under the Part 820 framework. FDA guidance provides recommendations; the applicable regulations establish the binding obligations.

The practical opportunity is to build evidence around intended use and meaningful risks. Reducing unnecessary documentation is useful only when the remaining evidence supports the decision that the system is fit for its intended purpose.

Computerized system validation: what CSV establishes

Computerized System Validation (CSV) is a lifecycle approach to establishing and maintaining documented confidence that a computerized system performs its intended functions. The work typically includes requirements, risk assessment, supplier evaluation, configuration, testing, review, release, and controlled operation.

For an individual system, define what it does, which records it creates or maintains, who uses it, and how a failure could affect product quality, patient safety, or data integrity. A generic “validated by the vendor” statement does not answer those questions.

CSV versus CSA: a useful distinction

Question Practical interpretation
What is CSV? A lifecycle approach to establishing and maintaining fitness for intended use.
What is CSA? A risk-based assurance approach described by FDA for specified medical-device production and QMS software.
Does CSA eliminate evidence? No. The assurance activity and its conclusion still need appropriate objective evidence.
Must every system use the same testing method? Choose methods and rigor based on intended use, relevant risks, and the applicable framework.

Choose the right framework for the system

Medical-device production and QMS software

Evaluate the current FDA CSA guidance and applicable Part 820 requirements. Distinguish these systems from software that performs a medical-device function itself.

Pharmaceutical manufacturing and quality systems

Assess the applicable drug cGMP obligations and electronic-record requirements. A medical-device guidance document does not automatically change the requirements for an electronic batch record, laboratory system, or manufacturing calculation.

Clinical-investigation systems

FDA’s October 2024 guidance on electronic systems, records, and signatures in clinical investigations addresses sponsors, investigators, IRBs, and contract research organizations. Clinical systems need an assessment tied to their actual use, data, and responsibilities.

For clinical platforms, BioBoston CRO’s EDC vendor qualification support helps sponsors evaluate the supplier and evidence relevant to study needs.

A risk-based software validation workflow

  1. Define intended use. Identify business processes, regulated records, users, interfaces, and boundaries.
  2. Assess failures. Consider what could go wrong and how the failure would be detected or controlled.
  3. Evaluate supplier evidence. Determine what can be relied on, what is missing, and which site-specific configurations need assessment.
  4. Select assurance activities. Choose testing and review methods proportionate to the risks and applicable obligations.
  5. Capture objective evidence. Retain enough information to understand what was evaluated, the result, and unresolved issues.
  6. Approve release. Document the conclusion and any constraints, with accountable review.
  7. Maintain control. Assess changes, incidents, access, backups, periodic review, and retirement.

Audit trails and electronic signatures

Determine whether 21 CFR Part 11 applies to the relevant records and signatures, together with the underlying predicate rules. Assess access controls, record protection, traceability of changes, signature meaning, and links between signatures and records as appropriate.

Test the controls in context. For example, check whether a changed result can be traced, whether permissions match responsibilities, and whether records remain readable and retrievable after export.

What should the validation record contain?

  • System identity, version, configuration, and intended use.
  • Applicable requirements and the risk assessment.
  • Supplier evidence reviewed and its limitations.
  • Assurance methods, results, deviations, and resolutions.
  • Release decision, reviewers, and operational ownership.
  • Change control and ongoing review arrangements.

Common mistakes when interpreting FDA software validation updates

Avoid presenting guidance as a new law, applying a device-specific document to every regulated system, or measuring success only by document count. A sound approach makes the relationship between use, risk, evidence, and approval easier to understand.

Common questions about FDA software validation requirements

Does FDA’s 2026 CSA guidance replace CSV for all regulated software?

No. The February 2026 guidance addresses medical-device production and quality management system software. Drug-manufacturing systems, clinical-investigation platforms, and software that is itself a medical device require assessment under their applicable frameworks. The guidance should not be presented as a universal validation exemption.

Can risk-based assurance include unscripted testing?

Yes, where appropriate to the function, risk, and applicable framework. Unscripted testing still needs meaningful objective evidence of what was assessed, the result, identified issues, and the conclusion. It does not mean undocumented testing or removal of accountable review.

What information should be gathered before choosing a CSV or CSA approach?

Start with intended use, regulated activities and records, system boundaries, configuration, interfaces, failure risks, supplier evidence, and operational ownership. These inputs help determine appropriate assurance activities. Choosing an approach solely to reduce document count can miss the evidence needed for the release decision.

Sources and regulatory references

References checked November 5, 2026. Regulations set binding obligations; agency guidance provides recommendations. Apply the sources within their stated scope and the requirements relevant to your product, activity, and jurisdiction.